116
VOLUME 8 NUMBER 3 • SEPTEMBER 2011
DIABETES EDUCATOR’S FOCUS
SA JOURNAL OF DIABETES & VASCULAR DISEASE
ing and HbA
1c
could test less frequently than patients who
are not at target.
Conclusion
There is no doubt that most type 2 diabetes patients should be
doing SMBG. It is important for health professionals to train
their patients in the use of the equipment and interpretation
of the results. This self-empowerment of type 2 diabetics is
critical. With the increase in incidence of diabetes worldwide,
healthcare professionals need to empower patients to moni-
tor themselves. The results of SMBG should be downloaded
and discussed with the patient on each visit to the healthcare
professional. Remember that HbA
1c
testing is done to detect
poor glycaemic control and should be carried out at least twice
a year on all diabetes patients, but SMBG should be available
to help improve glycaemic control and assess changes that
should be made to the medication.
References
The Diabetes Control and Complications Trial Research Group. The effect of
1.
intensive treatment of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus.
N Engl J Med
1993;
329
:
977–986.
EvansJM,NewtonRW,RutaDA,MacDonaldTM,StevensonRJ,MorrisAD.Frequency
2.
of blood glucose monitoring in relation to glycaemic control: observational study
with diabetes database.
Br Med J
1999;
319
: 83–86.
Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of
3.
blood glucose concentrations on glycated hemoglobin levels in diabetic patients
not taking insulin: a blinded, randomized trial.
Am J Med
2005;
118
(4): 422–425
O’Kane MJ, Bunting B, Copeland M, Coates VE, ESMON study group. Efficacy of
4.
self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes
(ESMON study): randomised controlled trial.
Br Med J
2008;
336
(7654): 1174–
1177.
Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A,
5.
et al
. Impact of self
monitoring of blood glucose in the management of patients with non-insulin
treated diabetes: open parallel group randomised trial.
Br Med J
2007;
335
(7611):
132.
Guerci B, Drouin P, Grangé V,
6.
et al
. ASIA group. Self-monitoring of blood glucose
significantly improves metabolic control in patients with type 2 diabetes mellitus:
the Auto-Surveillance Intervention Active (ASIA) study.
Diabetes Metab
2003;
29
:
587–594.
Schwedes U, Siebolds M, Mertes G, SMBG study group. Meal-related structured
7.
self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated
type 2 diabetic patients.
Diabetes Care
2002;
25
: 1928–1932.
Barnett AH, Krentz AJ, Strojek K,
8.
et al
. The efficacy of self-monitoring of blood
glucose in the management of patients with type 2 diabetes treated with a
gliclazide modified release-based regimen. A multicentre, randomized, parallel-
group, 6-month evaluation (DINAMIC 1 study).
Diabetes Obes Metab
2008;
10:
1239–1247.
McAndrew L, Schneider SH, Burns E, Leventhal H. Does patient blood glucose
9.
monitoring improve diabetes control? A systematic review of the literature.
Diabetes Educ
2007;
33
(6): 991–1011.
Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. Self-monitoring of blood glucose
10.
as part of a multi-component therapy among non-insulin requiring type 2 diabetes
patients: a meta-analysis (1966–2004).
Curr Med Res Opin
2005;
21
(2): 173–184.
Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-
11.
analysis of direct and indirect comparisons.
Curr Med Res Opin
2006;
22
(4): 671–
681.
Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter
12.
LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not
using insulin: a systematic review.
Diabetes Care
2005;
28
(6): 1510–1517.
Kempf K, Neukirchen W, Martin S, Kolb H. Self-monitoring of blood glucose in type
13.
2 diabetes: a new look at published trials.
Diabetologia
2008;
51
(4): 686–688.
Poolsup N, Suksomboon, N, Jiamsathit W. Systematic review of the benefits of
14.
self-monitoring of blood glucose on glycemic control in type 2 diabetes patients.
Diabetes Technol Ther
2008;
10
(Suppl 1): S51–66.
Towfigh A, Romanova M, Weinreb JE, Munjas B, Suttorp MJ, Zhou A, Shekelle PG.
15.
Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus
not taking insulin: a meta-analysis.
Am J Manag Care
2008;
14
(7): 468–475.
Klonoff DC, Bergenstal R, Blonde LS,
16.
et al.
Consensus report of the coalition for
clinical research-self-monitoring of blood glucose.
J Diabetes Sci Technol
2008;
2
(6): 1030–1053.
Cohen SL, Legg S, Bird R. A bedside method of blood-glucose estimation.
17.
Lancet
1964;
2
(7365): 883–884.
UK Prospective Diabetes study (UKPDS) group: Intensive blood-glucose control
18.
with sulphonylureas or insulin compared with conventional treatment and risk of
complications in patients with type 2 diabetes (UKPDS 33).
Lancet
1998;
352
:
837–853.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA,
19.
et al.
Association of glycaemia with macrovascular and microvascular complications of
type 2 diabetes (UKPDS 35): prospective observational study.
Br Med J
2000;
321:
405–412.
Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk
20.
factor for diabetic complications.
J Am Med Assoc
2006;
295
:1707–1708.
Epidemiology of Diabetes interventions and complications reserach group (EDIC):
21.
Diabetes Care
1999;
22
: 99–111.
Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. The effect of glycemic
22.
exposure on the risk of microvascular complications in the Diabetes Control and
Complications Trial
–
revisited.
Diabetes
2008;
57
: 995–1001.
Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA
23.
1c
in the
prediction of cardiovascular disease in type 1.
Diabetologia
2008;
51:
365–371.
Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of
24.
microvascular complications in type 1 diabetes.
Diabetes Care
2006;
29:
1486–
1490.
Bonomo K, De Salve A, Fiora E, Mularoni E, Massucco P, Poy P,
25.
et al
. Evaluation of
a simple policy for pre- and post-prandial blood glucose self-monitoring in people
with type 2 diabetes not on insulin.
Diabetes Res Clin Prac
2010;
87:
246
–
251.
Duran
26.
a, Martin N, Runkle I, Perez N, Abad R, Fernandez M,
et al.
Benefits of SMBG
in the management of new-onset T2DM: The St. Carlos Study, a prospective RCT
J Diabetes
2010;
2
: 203–211.
Kempf K, Kruse J, Martin NS. ROSSO-in-praxi: a self-monitoring of blood glucose-
27.
structured 12-week lifestyle intervention significantly improves glucometabolic
control of patients with T2DM.
Diabetes Technol Therapeut
2010;
12
(7): 2010.
IDF Clinical Guidelines task force for type 2 diabetes 2009.
28.
.
Schnell O,
29.
et al
. on behalf of the European Expert Consensus Panel (Munich 2009)
Consensus Statement on Self Monitoring of Blood Glucose in Diabetes. A European
Perspective.
Diabetes, Stoffwechsel und Herz
2009;
18
: 285
–
289.
National Institute for Health and Clinical Excellence. Type 2 diabetes: the management
30.
of type 2 diabetes. NICE clinical guideline 66. [cited 2008 November 17]; Available
from:
.
TheDiabetesControlandComplicationstrial/EpidemiologyofDiabetes Interventions
31.
and Complications (DCCT/EDIC) study research group: Intensive diabetes treatment
and cardiovascular disease in patients with type 1 diabetes.
N Engl J Med
2005;
353
: 2643–2653.
Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk
32.
factor for diabetic complications.
J Am Med Assoc
2006;
295
: 1707–1708.
Polonsky WH, Lawrence F, Shickman CH,
33.
et al
. Structured self-monitoring of blood
glucose significantly reduces A1C levels in poorly controlled, non-insulin-treated
type 2 diabetes.
Diabetes Care
2011;
34
(2): 262
–
267.
It's the
shell that
makes
safer.
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
